9 Spinal Muscular Atrophy Clinical Trials in Hackensack, NJ (2026)

Q: How do I join a clinical trial in Hackensack?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Hackensack

NCT04165798Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a...

Hackensack, NJ1,065 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04165070Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

Hackensack, NJ450 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06780137Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

Hackensack, NJ327 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07046923Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the blood...

Hackensack, NJ240 participantsEli Lilly and Company

View Study Details

NCT07227597Recruiting

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other par...

Hackensack, NJ170 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06116786Recruiting

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy....

Hackensack, NJ126 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT07080242Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroen...

Hackensack, NJ120 participantsSystImmune Inc.

View Study Details

NCT06630806Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 wil...

Hackensack, NJ87 participantsSanofi

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Hackensack, NJ40 participantsAstellas Pharma Global Development, Inc.

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Hackensack

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 9 spinal muscular atrophy clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 2,625 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Eli Lilly and Company, Johnson & Johnson Enterprise Innovation Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Hackensack — FAQ

Are there spinal muscular atrophy clinical trials in Hackensack?

Yes, there are 9 spinal muscular atrophy clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 9 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated July 13, 2026 from ClinicalTrials.gov